Pharmaceutical amyloidosis associated with subcutaneous insulin and enfuvirtide administration Journal Article


Authors: D'Souza, A.; Theis, J. D.; Vrana, J. A.; Dogan, A.
Article Title: Pharmaceutical amyloidosis associated with subcutaneous insulin and enfuvirtide administration
Abstract: Protein and peptide drugs administered subcutaneously, such as insulin can be amyloidogenic and result in localized amyloid deposits at the sites of medication injections. These iatrogenic amyloidoses typically present as a localized subcutaneous nodule or skin reaction at the site of administration, and often pose diagnostic challenges. We have analyzed the amyloid proteome in 52 cases of insulin and enfuvirtide associated amyloidosis using laser microdissection/tandem mass spectrometry. We show that the deposits are composed of the drug, as well as other amyloid precursor proteins such as apolipoproteins A-I, A-IV, E and serum amyloid protein. Mass spectrometry-based amyloid sub-typing allows for accurate amyloid diagnosis with resultant therapeutic and prognostic implications. This insight into the amyloid proteome in drug-induced amyloidosis may help further understand pathogenesis of amyloid fibril formation. © 2014 Informa UK Ltd. All rights reserved.
Keywords: iatrogenic; drug-induced amyloid; pharmaceutical amyloidosis
Journal Title: Amyloid
Volume: 21
Issue: 2
ISSN: 1350-6129
Publisher: Taylor & Francis Group  
Date Published: 2014-06-01
Start Page: 71
End Page: 75
Language: English
DOI: 10.3109/13506129.2013.876984
PROVIDER: scopus
PMCID: PMC4021035
PUBMED: 24446896
DOI/URL:
Notes: Amyloid -- Export Date: 2 June 2014 -- CODEN: AIJIE -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Ahmet Dogan
    454 Dogan